CN103494202A - Healthcare food with antioxidant function - Google Patents
Healthcare food with antioxidant function Download PDFInfo
- Publication number
- CN103494202A CN103494202A CN201310489756.2A CN201310489756A CN103494202A CN 103494202 A CN103494202 A CN 103494202A CN 201310489756 A CN201310489756 A CN 201310489756A CN 103494202 A CN103494202 A CN 103494202A
- Authority
- CN
- China
- Prior art keywords
- parts
- group
- healthcare food
- health food
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003963 antioxidant agent Substances 0.000 title abstract description 10
- 230000003078 antioxidant effect Effects 0.000 title abstract description 10
- 235000013305 food Nutrition 0.000 title abstract 7
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 15
- 244000068988 Glycine max Species 0.000 claims abstract description 11
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 11
- 239000000787 lecithin Substances 0.000 claims abstract description 11
- 235000010445 lecithin Nutrition 0.000 claims abstract description 11
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 8
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 8
- 239000002775 capsule Substances 0.000 claims description 48
- 235000013402 health food Nutrition 0.000 claims description 23
- 239000002994 raw material Substances 0.000 claims description 22
- 230000003064 anti-oxidating effect Effects 0.000 claims description 15
- 235000013761 grape skin extract Nutrition 0.000 claims description 14
- 235000013871 bee wax Nutrition 0.000 claims description 8
- 239000012166 beeswax Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 235000021388 linseed oil Nutrition 0.000 claims description 8
- 239000000944 linseed oil Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 4
- 229940083466 soybean lecithin Drugs 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 6
- 230000007423 decrease Effects 0.000 abstract description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract 2
- 108010012715 Superoxide dismutase Proteins 0.000 abstract 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- 102000006587 Glutathione peroxidase Human genes 0.000 abstract 1
- 108700016172 Glutathione peroxidases Proteins 0.000 abstract 1
- 230000009982 effect on human Effects 0.000 abstract 1
- 239000000284 extract Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000032683 aging Effects 0.000 description 9
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical group C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 9
- 210000004291 uterus Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 230000002611 ovarian Effects 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000008717 functional decline Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000012639 Balance disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010027304 Menopausal symptoms Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000002605 anti-dotal effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 231100000880 dysequilibrium Toxicity 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 230000029860 luteolysis Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000955 neuroendocrine Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- -1 oxygen free radical Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to the technical field of healthcare food, in particular to a healthcare food with antioxidant function. The healthcare food is made by 50-150 parts of haematococcus pluvialis, 50-150 parts of grate skin extracts, 10-100 parts of soya bean lecithin, 90 parts of safflower and 1.5 parts of oryzanol according to weight. Taking the healthcare food can increase content of SOD (superoxide dismutase), T-AOC (total-antioxidative capacity) and GSH-Px (glutathione peroxidase) in blood serum and decrease H2O2 content, and the healthcare food is remarkable in effect and capable of expelling in-vivo free radicals, has certain antioxidant function and can improve antioxidant ability in climacteric. Besides, the healthcare food is simple in recipe, easy to manufacture and low in side effect on humans.
Description
technical field
The present invention relates to the health food technology field, particularly a kind of health food with anti-oxidation function.
background technology
Aging typically refers under normal condition after the biological development maturation, increases with the age, and self hypofunction, homeostasis ability and stress ability decline, the progressively retrogression of structure, function, deathward, irreversible phenomenon.Aging is a kind of biological process of complexity, is zoic common trait.Aging is divided into physiological aging and pathological seaility two classes, and the physiological aging is the retrogression that organism must occur in the growth overall process, and pathological seaility is the aging caused due to various diseases.Most of the elderlys, both often exist simultaneously and interact, can not be well-separated.
Enter 21 century, along with continuing to increase of the aged, aging population has become global social concern, and antidotal research has become the focus of international the world of medicine.
Modern medicine mainly contains free radical theory, tolemerase, gene regulation theory, injury of mitochondria theory etc. to the research of Aging mechanism, mainly contain antioxidant for antidotal medicine, antiaging hormone, the nutrient classes such as protein, nucleic acid, each seed amino acid, MAOI, immunomodulator etc.
Menopausal syndrome is due to ovarian function decline, and the ovarian secretion hormone reduces and the symptom of the neuroendocrine dysequilibrium that causes, and clinical manifestation is paramenia, insomnia, failure of memory and depression, anxiety etc.Ovarian function decline and hormone secretion reduce all and increase with the interior activities of antioxidant enzymes decline of ovary tissue, content of oxygen free radical, luteolysis, the interior mitochondria of ovary and immune variation etc. are related.So far the good method still well do not delayed senility.
summary of the invention
In order to solve the problem of above aging, the invention provides and a kind ofly can remove interior free yl, there is certain antioxidation, can improve the health food of climacteric oxidation resistance.
The present invention is achieved by the following measures:
A kind of health food with anti-oxidation function, the raw material weight proportioning is as follows:
Haematococcus pluvialis 50-150 part, grape skin extract 50-150 part, soybean lecithin 10-100 part.
Described health food, the raw material weight proportioning is as follows:
90 parts of haematococcus pluvialis, 90 parts of grape skin extracts, 20 parts of soybean lecithins.
A kind of health food with anti-oxidation function, the raw material weight proportioning is as follows:
Haematococcus pluvialis 50-150 part, grape skin extract 50-150 part, soybean lecithin 10-100 part, safflower 50-150 part, oryzanol 0.5-3 part.
Described health food, the raw material weight proportioning is as follows:
90 parts of haematococcus pluvialis, 90 parts of grape skin extracts, 20 parts of soybean lecithins, 90 parts, safflower, 1.5 parts of oryzanol.
Described health food, make capsule, tablet or granule after raw material is mixed.
Described health food, is characterized in that adding beeswax 10-100 part, linseed oil 150-400 part to make capsule.
Beneficial effect of the present invention:
Health food of the present invention, can improve SOD in serum, T-AOC and GSH-Px, reduces H
2o
2content, successful, can remove interior free yl, has certain antioxidation, can improve the climacteric oxidation resistance; And formula is simple, be easy to make; Little to the human body side effect.
The specific embodiment
For a better understanding of the present invention, below in conjunction with specific embodiment, further illustrate.
embodiment 1:
A kind of health food with anti-oxidation function, the raw material weight proportioning is as follows:
50 parts of haematococcus pluvialis, 150 parts of grape skin extracts, 10 parts of soybean lecithins.
After being mixed, raw material makes capsule, tablet or granule.
Add 150 parts of 100 parts, beeswax and linseed oil to make capsule.
embodiment 2:
A kind of health food with anti-oxidation function, the raw material weight proportioning is as follows:
150 parts of haematococcus pluvialis, 50 parts of grape skin extracts, 100 parts of soybean lecithins.
After being mixed, raw material makes capsule, tablet or granule.
Add 400 parts of 10 parts, beeswax and linseed oil to make capsule.
embodiment 3:
A kind of health food with anti-oxidation function, the raw material weight proportioning is as follows:
90 parts of haematococcus pluvialis, 90 parts of grape skin extracts, 20 parts of soybean lecithins.
After being mixed, raw material makes capsule, tablet or granule.
Add 280 parts of 20 parts, beeswax and linseed oil to make capsule.
embodiment 4:
A kind of health food with anti-oxidation function, the raw material weight proportioning is as follows:
90 parts of haematococcus pluvialis, 90 parts of grape skin extracts, 20 parts of soybean lecithins, 90 parts, safflower, 1.5 parts of oryzanol.
After being mixed, raw material makes capsule, tablet or granule.
Add 280 parts of 20 parts, beeswax and linseed oil to make capsule.
embodiment 5:
A kind of health food with anti-oxidation function, the raw material weight proportioning is as follows:
50 parts of haematococcus pluvialis, 150 parts of grape skin extracts, 10 parts of soybean lecithins, 150 parts, safflower, 3 parts of oryzanol.
After being mixed, raw material makes capsule, tablet or granule.
Add 150 parts of 100 parts, beeswax and linseed oil to make capsule.
embodiment 6:
A kind of health food with anti-oxidation function, the raw material weight proportioning is as follows:
150 parts of haematococcus pluvialis, 50 parts of grape skin extracts, 100 parts of soybean lecithins, 50 parts, safflower, 0.5 part of oryzanol.
After being mixed, raw material makes capsule, tablet or granule.
Add 400 parts of 10 parts, beeswax and linseed oil to make capsule.
the compliance test result experiment
1 materials and methods
1.1 animal
Healthy Wistar female rats of 11～12 monthly ages, weight 180～200g,, provided by Shandong University's Experimental Animal Center by 30.
1.2 medicine, reagent and instrument
The capsule prepared in embodiment 1-3, for by our company's self-control, be mixed with the solution for standby of active constituent content 0.5g/mL with distilled water; Isoflavones, Nanning Fresh-life Technology Co., Ltd.'s product.Chloraldurate, space Longhai City, Qingdao algae Co., Ltd product; SOD, T-AOC, H
2o
2with the GSH-Px detection kit, Nanjing is built up bio-engineering research and is provided.The CT14RD table-type high-speed refrigerated centrifuge, sky, Shanghai U.S. biochemical instrument plant engineering Co., Ltd product; The VIS-723N visible spectrophotometer, Beijing Rayleigh Analytical Instrument Co.,Ltd's product; The digital display thermostat water bath, Zhengzhou Tu Fu instrument plant product.
1.3 foundation and the drug intervention of animal grouping, model
42 healthy Wistar female rats are divided into to 7 groups of the blank group (castration group) of sham-operation group, castration, isoflavones group, embodiment 1 Capsules group, embodiment 2 Capsules group, embodiment 3 Capsules group and embodiment 4 Capsules group, 6 every group at random.Adopt excision bilateral ovaries method to set up rat climacteric model, and make the colpocytology smear and determine that whether model is successful.Sham-operation group and castration group give physiological saline 0.01mL/g weight, and the isoflavones group gives isoflavones 0.4mg/g weight, and the embodiment group gives 5mg solution/g weight.Every day, gavage was 1 time, continuously 15d.
1.4 detection index
In experimentation every 3d to rat Weighing body quality.After drug intervention finishes, 100g/L chloral hydrate anesthesia rat, abdominal aortic blood, 2500r/min, centrifugal 10min, get serum, and-20 ℃ save backup.The strict kit specification of pressing is measured SOD, T-AOC, H in serum
2o
2and GSH-Px.
1.5 statistical method
Adopt the SPSS13.0 statistical analysis software to process.Data with mean (
) ± standard deviation (S) means, carries out one-way analysis of variance or non-parametric test.Take P<0.05 has statistical significance as difference.
2 results
2.1 respectively organize the contrast of rat weight
Indivedual animal deads in experimentation.With the sham-operation group, contrast, respectively organize weight difference not statistically significant (P > 0.05) before modeling and before intervening, after the castration group is intervened 9d, 12d and 15d, difference has statistical significance (P<0.05), and other respectively organize difference not statistically significant (P > 0.05).With the contrast of castration group, each drug intervention group weight difference not statistically significant.With the contrast of sham-operation group, all the other respectively organize weight all growth, and wherein the increase of castration group is the most obvious; With the contrast of castration group, each drug intervention group growth of weight is relatively slow.In Table 1.
Table 1 is respectively organized the contrast of rat weight
Annotate: with the sham-operation group, compare,
*p<0.05.
2.2 respectively organize the rat uterus index contrast
With the contrast of sham-operation group, other respectively organize uterus index decline, and difference has statistical significance (P<0.05).With the contrast of castration group, each drug intervention group uterus index increases, and wherein embodiment 2 Capsules group, embodiment 3 Capsules group and embodiment 4 Capsules group increase difference statistical significance (P<0.05).With the contrast of isoflavones group, embodiment 2 Capsules group, embodiment 3 Capsules group and embodiment 4 Capsules group uterus indexes increase, and difference has statistical significance (P<0.01).In Table 2
Table 2 is respectively organized the rat uterus index contrast
| Group | Number of animals | Uterus index |
| The sham-operation group | 6 | 0.231±0.042 |
| The castration group | 6 | 0.041±0.009 * |
| The isoflavones group | 5 | 0.045±0.006 * |
| Embodiment 1 Capsules group | 5 | 0.052±0.003 * |
| Embodiment 2 Capsules group | 6 | 0.059±0.007 *＃△△ |
| Embodiment 3 Capsules group | 6 | 0.061±0.004 *＃△△ |
| Embodiment 4 Capsules group | 6 | 0.065±0.002 *＃△△ |
Annotate: with the sham-operation group, compare,
*p<0.05; With the contrast of castration group,
#p<0.05; With the contrast of isoflavones group,
△ △p<0.01.
2.3 respectively organize Antioxidant Indexes contrast in rat blood serum
With the sham-operation group, contrast, all the other are respectively organized SOD content in serum, T-AOC content and GSH-Px vigor and descend, castration group and isoflavones group SOD, GSH-Px difference have statistical significance (P<0.05 or P<0.01), and each organizes T-AOC content difference statistical significance (P<0.01); Each organizes H in serum
2o
2content obviously increases (P<0.01).With the castration group, contrast, SOD content in each drug intervention group serum, T-AOC content and GSH-Px vigor increase, wherein embodiment 1 Capsules group, embodiment 2 Capsules group, embodiment 3 Capsules group and embodiment 4 Capsules group SOD, the increase of T-AOC content the most obviously (P<0.01); H in each drug intervention group serum
2o
2content reduces, and difference has statistical significance (P<0.01).With the contrast of isoflavones group, in embodiment 1 Capsules group, embodiment 2 Capsules group, embodiment 3 Capsules group and embodiment 4 Capsules group serum, SOD content, T-AOC content and GSH-Px vigor increase, and difference has statistical significance (P<0.05 or P<0.01); H in embodiment 1 Capsules group, embodiment 2 Capsules group, embodiment 3 Capsules group and embodiment 4 Capsules group serum
2o
2content obviously reduces (P<0.01).In Table 3
Table 3 is respectively organized rat blood serum SOD, T-AOC, H
2o
2and GSH-Px contrast
| Group | Number of animals | SOD/(U·mL -1) | T-AOC(U·mL -1) | H 2O 2/( mmol·L -1) | GSH-Px/( U·L -1) |
| The sham-operation group | 6 | 114.08±20.16 | 10.21±0.91 | 17.42±1.69 | 1610.34±51.04 |
| The castration group | 6 | 61.26±23.54 ** | 6.85±0.72 ** | 66.71±4.07 ** | 1279.63±159.31 * |
| The isoflavones group | 5 | 78.13±21.42 * | 7.27±0.69 ** | 43.24±1.92 **＃＃ | 1378.83±28.06 ** |
| Embodiment 1 Capsules group | 5 | 101.25±16.71 ＃＃△ | 8.11±0.62 **＃＃△△ | 32.54±2.18 **＃＃△△ | 1522.44±32.24 △△ |
| Embodiment 2 Capsules group | 6 | 104.66±12.47 ＃＃△ | 8.74±0.59 **＃＃△△ | 30.27±2.15 **＃＃△△ | 1550.06±21.87 △△ |
| Embodiment 3 Capsules group | 6 | 107.24±14.03 ＃＃△ | 8.98±0.48 **＃＃△ | 26.76±2.04 **＃＃△△ | 1597.14±20.21 △△ |
| Embodiment 3 Capsules group | 6 | 112.48±13.15 ＃＃△ | 9.23±0.34 **＃＃△ | 22.25±2.13 **＃＃△△ | 1632.23±20.85 △△ |
Annotate: with the sham-operation group, compare,
*p<0.05,
*p<0.01; With the contrast of castration group,
##p<0.01; With the contrast of isoflavones group,
△p<0.05,
△ △p<0.01.
3 discuss
Menopausal syndrome is due to ovarian function decline, and the ovarian secretion hormone reduces and the symptom of the neuroendocrine dysequilibrium that causes, and clinical manifestation is paramenia, insomnia, failure of memory and depression, anxiety etc.Ovarian function decline and hormone secretion reduce all and increase with the interior activities of antioxidant enzymes decline of ovary tissue, content of oxygen free radical, luteolysis, the interior mitochondria of ovary and immune variation etc. are related.T-AOC is the index of weighing body antioxidant system integration capability, can reflect on the whole the level of antioxidant ability of organism; SOD is free radical and MDA scavenger in cell, can be converted into H to harmful superoxide radical
2o
2; H in cell
2o
2can be transformed into the high activity hydroxy radical, cause the fracture of DNA chain; GSH-Px
Produce the chain reaction of various free radicals in mitochondrial respiratory chain electron transfer process capable of blocking, avoid cell to be subject to the damage of peroxide.
This result of study shows, castration group Weight gain, and uterus index reduces, and with the contrast of sham-operation group, difference has statistical significance, illustrates that ovary and changes of body mass and uterus index have substantial connection, and its mechanism awaits further discussion.In castration group rat blood serum, SOD, T-AOC and GSH-Px reduce, H
2o
2increase; Give after the different pharmaceutical effect SOD, T-AOC and GSH-Px in serum and improved in various degree, H
2o
2content reduces, and wherein embodiment 3 Capsules group effects are the most obvious, and hence one can see that, and health products of the present invention can be removed interior free yl, have certain antioxidation, can improve the hot flushes in rats oxidation resistance.
Claims (6)
1. the health food with anti-oxidation function is characterized in that the raw material weight proportioning is as follows:
Haematococcus pluvialis 50-150 part, grape skin extract 50-150 part, soybean lecithin 10-100 part.
2. health food according to claim 1 is characterized in that the raw material weight proportioning is as follows:
90 parts of haematococcus pluvialis, 90 parts of grape skin extracts, 20 parts of soybean lecithins.
3. the health food with anti-oxidation function is characterized in that the raw material weight proportioning is as follows:
Haematococcus pluvialis 50-150 part, grape skin extract 50-150 part, soybean lecithin 10-100 part, safflower 50-150 part, oryzanol 0.5-3 part.
4. health food according to claim 3 is characterized in that the raw material weight proportioning is as follows:
90 parts of haematococcus pluvialis, 90 parts of grape skin extracts, 20 parts of soybean lecithins, 90 parts, safflower, 1.5 parts of oryzanol.
5. according to the described health food of claim 1-4, after it is characterized in that raw material is mixed, make capsule, tablet or granule.
6. health food according to claim 5, is characterized in that adding beeswax 10-100 part, linseed oil 150-400 part to make capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310489756.2A CN103494202B (en) | 2013-10-18 | 2013-10-18 | A kind of health food with anti-oxidation function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310489756.2A CN103494202B (en) | 2013-10-18 | 2013-10-18 | A kind of health food with anti-oxidation function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103494202A true CN103494202A (en) | 2014-01-08 |
| CN103494202B CN103494202B (en) | 2015-08-19 |
Family
ID=49859541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310489756.2A Active CN103494202B (en) | 2013-10-18 | 2013-10-18 | A kind of health food with anti-oxidation function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103494202B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104643100A (en) * | 2015-02-11 | 2015-05-27 | 浙江康恩贝集团医疗保健品有限公司 | Health food with anti-oxidization function |
| CN104905321A (en) * | 2015-05-27 | 2015-09-16 | 中国科学院天津工业生物技术研究所 | Wall-breaking Haematoccoccus Pluvialis powder microcapsules and preparation process thereof |
| CN105919118A (en) * | 2016-05-03 | 2016-09-07 | 北京东方红航天生物技术股份有限公司 | Health-care food with antioxidant function |
| CN107173807A (en) * | 2017-06-13 | 2017-09-19 | 烟台燕园科玛健康产业有限公司 | A kind of anti-oxidation health alimentation composition containing algae extract |
| CN109315770A (en) * | 2018-09-19 | 2019-02-12 | 上海康成科技发展有限公司 | Anti-oxidant dietary supplements and its production method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002013835A1 (en) * | 2000-08-11 | 2002-02-21 | Ashni Naturaceuticals, Inc. | Composition exhibiting synergistic antioxidant activity |
| CN101322711A (en) * | 2008-01-09 | 2008-12-17 | 济南老来寿生物技术有限公司 | Health care medicament for resisting fatigue and enhancing immunity and preparation thereof |
| CN101352430A (en) * | 2007-07-25 | 2009-01-28 | 北京星昊医药股份有限公司 | Compound formulation containing carthamus tinctorius yellow colour B and uses thereof |
| CN102356874A (en) * | 2011-09-23 | 2012-02-22 | 北京康比特体育科技股份有限公司 | Antioxidant health food composition, and its preparation method and application |
-
2013
- 2013-10-18 CN CN201310489756.2A patent/CN103494202B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002013835A1 (en) * | 2000-08-11 | 2002-02-21 | Ashni Naturaceuticals, Inc. | Composition exhibiting synergistic antioxidant activity |
| CN101352430A (en) * | 2007-07-25 | 2009-01-28 | 北京星昊医药股份有限公司 | Compound formulation containing carthamus tinctorius yellow colour B and uses thereof |
| CN101322711A (en) * | 2008-01-09 | 2008-12-17 | 济南老来寿生物技术有限公司 | Health care medicament for resisting fatigue and enhancing immunity and preparation thereof |
| CN102356874A (en) * | 2011-09-23 | 2012-02-22 | 北京康比特体育科技股份有限公司 | Antioxidant health food composition, and its preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| 杨艳晖等: "大豆卵磷脂对小鼠的抗疲劳和抗氧化作用研究", 《现代生物医学进展》, vol. 11, no. 21, 30 November 2011 (2011-11-30), pages 4024 - 4026 * |
| 龚院生等: "γ-谷维醇对小鼠生理功能的影响", 《动物科学与动物医学》, vol. 19, no. 2, 28 February 2002 (2002-02-28), pages 26 - 28 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104643100A (en) * | 2015-02-11 | 2015-05-27 | 浙江康恩贝集团医疗保健品有限公司 | Health food with anti-oxidization function |
| CN104905321A (en) * | 2015-05-27 | 2015-09-16 | 中国科学院天津工业生物技术研究所 | Wall-breaking Haematoccoccus Pluvialis powder microcapsules and preparation process thereof |
| CN105919118A (en) * | 2016-05-03 | 2016-09-07 | 北京东方红航天生物技术股份有限公司 | Health-care food with antioxidant function |
| CN107173807A (en) * | 2017-06-13 | 2017-09-19 | 烟台燕园科玛健康产业有限公司 | A kind of anti-oxidation health alimentation composition containing algae extract |
| CN109315770A (en) * | 2018-09-19 | 2019-02-12 | 上海康成科技发展有限公司 | Anti-oxidant dietary supplements and its production method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103494202B (en) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103494202B (en) | A kind of health food with anti-oxidation function | |
| CN104826087B (en) | Compound Moringa polypeptide and its preparation method and application | |
| WO2022116807A1 (en) | Method for preparing ganoderma lucidum extract oil rich in ganoderma lucidum triterpene | |
| CN106994131B (en) | A kind of application adjusting lipid metaboli and fat compound PAQG in pharmacy | |
| CN102907677A (en) | Sea-buckthorn perilla seed oil soft capsule having function of assisting blood-fat reduction and preparation method thereof | |
| CN106722934B (en) | Anti-aging health food containing earthworm and clam worm peptide-containing extract | |
| CN102389115A (en) | Health food for alleviating visual fatigue and preparation method and application thereof | |
| US20100099918A1 (en) | Tranquilizer and Functional Food | |
| CN104825573A (en) | Anti-fatigue application of raspberry seed oil | |
| CN108514114A (en) | Composition for relieving physical fatigue and purposes based on chondriosome nutrient theory | |
| WO2016141774A1 (en) | Uses of jilin ginseng oligopeptide in preparing food product or healthcare food product for improving and enhancing sexual function | |
| CN105211865A (en) | A kind of black fruit lyceum ferment and preparation method thereof | |
| JP6034834B2 (en) | Kampo herbal composition for anti-uterine myoma and method for producing anti-uterine fibroid drug produced by herbal herbal extract | |
| JP2004131482A (en) | Anti-aging/climacteric symptom relief by using ganoderma lucidium spore | |
| CN105054068A (en) | Saccharomyces cerevisiae glutathione nutritional preparation | |
| CN105495153A (en) | Antioxidant health-care product containing phycocyanin and ginkgo leaf extracts | |
| Zhang et al. | Fermentation enhances the amelioration effect of bee pollen on Caco-2 monolayer epithelial barrier dysfunction based on NF-κB-mediated MLCK-MLC signaling pathway | |
| CN103054043B (en) | Composite capsule for delaying senescence | |
| WO2020137254A1 (en) | Microalgae-containing product and production method therefor | |
| CN108379446B (en) | Coenzyme Q10 preparation for adjuvant treatment of male oligospermia and preparation method thereof | |
| CN104839689A (en) | Health product for invigorating spleen, nourishing stomach, resisting fatigue and enhancing immunity | |
| CN103789084A (en) | Pine-seed oil and preparation method and use thereof | |
| CN108720020B (en) | Application of wolfberry seed oil or nitraria seed oil in reducing blood sugar | |
| US20240180815A1 (en) | Methods for resisting skin aging by using kiwiberry extract | |
| CN108236714B (en) | Composition for relieving physical fatigue and assisting in reducing blood fat and soft capsule thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 2000 Shun Tai Plaza Building 9, room 0604 Patentee after: Jinan Laolaishou Biological Co., Ltd. Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 2000 Shun Tai Plaza Building 9, room 0604 Patentee before: Jinan Laolaishou Biology Co., Ltd. |
|
| CP02 | Change in the address of a patent holder |
Address after: 250101 Shandong Province Jinan High-tech Zone Xinlu Street 1666 Sanqing Qisheng Square 5 Floor 8 Patentee after: Jinan Laolaishou Biological Co., Ltd. Address before: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 2000 Shun Tai Plaza Building 9, room 0604 Patentee before: Jinan Laolaishou Biological Co., Ltd. |
|
| CP02 | Change in the address of a patent holder |